Oppenheimer Initiates Coverage On City Therapeutics with Outperform Rating, Announces Price Target of $46
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsInitiationPrice Target
Oppenheimer analyst Joseph Thomas initiates coverage on City Therapeutics (NASDAQ:CTY) with a Outperform rating and announces Price Target of $46.
Oppenheimer analyst Joseph Thomas initiates coverage on City Therapeutics (NASDAQ:CTY) with a Outperform rating and announces Price Target of $46.